

Oasmia to present at Penser's cancer research day October 7

Uppsala, Sweden, September 25 2020 – Oasmia Pharmaceutical's CEO, Dr Francois Martelet will present at Erik Penser Bank's cancer research day October 7, 2020, at 10:05. The presentation will be live streamed via Erik Penser Bank's Youtube-channel, Penser Play: https://www.youtube.com/channel/UCLmAEBHTXLIXnuyVQ2TRHeQ/search?query=bolagsdag

For more information:

Oasmia Pharmaceutical AB

Francois Martelet, Chief Executive Officer

Phone: +46 18-50 54 40 E-mail: IR@oasmia.com

Consilium Strategic Communications

Jonathan Birt, Chris Welsh, Ashley Tapp

Phone: +44 (0)20 3709 5700

E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Oasmia produces novel formulations of wellestablished cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on Oasmia's proprietary technology platform XR17™. Oasmia has been successful in moving its first product candidate, Apealea® (paclitaxel micellar), through clinical development, and has received market authorization in the European Union and other territories. Oasmia is in the process of transitioning into the commercialization phase of the product Apealea and making the product accessible to patients via its partnership with Elevar and its existing operations and partnerships in its retained territories. The company's shares are traded on Nasdaq Stockholm (ticker: OASM). Visit www.oasmia.com for further information.

Attachments

Oasmia to present at Penser's cancer research day October 7